Q-omics provides the consensus-scored NCF1B profile across patient tissues and cancer cell-line models. NCF1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NCF1B is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, NCF1B RNA expression shows 22,355 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where NCF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCF1B survival associations across molecular data types. NCF1B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCF1B RNA expression–survival associations across cancer types. High NCF1B expression shows unfavorable associations in LGG and UVM, but favorable associations in HNSC, SKCM, CESC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NCF1B RNA expression.
This table summarizes NCF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NCF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCF1B shows lower tumor expression in COAD, LUSC, LUAD and BLCA and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher NCF1B RNA expression in normal versus tumor tissue (log2 FC = −1.092, t-test p < 0.001).
This table shows molecular features associated with NCF1B in patient tissues and cancer cell lines. In patient samples, NCF1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
